RA Session II
2021
In 2021, RA Session II earned a total compensation of $4.6M as President, Chief Executive Officer and Director at Taysha Gene Therapies, a 3% decrease compared to previous year.
Compensation breakdown
Option Awards | $4,028,250 |
---|---|
Salary | $542,800 |
Other | $150 |
Total | $4,571,200 |
Session received $4M in option awards, accounting for 88% of the total pay in 2021.
Session also received $542.8K in salary and $150 in other compensation.
Rankings
In 2021, RA Session II's compensation ranked 2,899th out of 12,415 executives tracked by ExecPay. In other words, Session earned more than 76.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,899 | 77th |
Manufacturing | 1,154 | 79th |
Chemicals And Allied Products | 460 | 81st |
Drugs | 404 | 81st |
Biological Products, Except Diagnostic Substances | 116 | 74th |
Session's colleagues
We found two more compensation records of executives who worked with RA Session II at Taysha Gene Therapies in 2021.